NLRP3 inflammasome activation in cancer: a double-edged sword
S Hamarsheh, R Zeiser - Frontiers in immunology, 2020 - frontiersin.org
Inflammation is involved in tumor development and progression as well as antitumor
response to therapy. In the past decade, the crosstalk between inflammation, immunity, and …
response to therapy. In the past decade, the crosstalk between inflammation, immunity, and …
Angiogenesis and anti-angiogenic treatment in prostate cancer: mechanisms of action and molecular targets
E Ioannidou, M Moschetta, S Shah, JS Parker… - International journal of …, 2021 - mdpi.com
Prostate cancer (PC) is the most common cancer in men and the second leading cause of
cancer-related death worldwide. Many therapeutic advances over the last two decades have …
cancer-related death worldwide. Many therapeutic advances over the last two decades have …
Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis
Context Venous thromboembolism is one of the leading causes of morbidity and mortality in
patients with cancer. Concerns have arisen regarding the risk of venous thromboembolism …
patients with cancer. Concerns have arisen regarding the risk of venous thromboembolism …
Crosstalks between inflammasome and autophagy in cancer
Both inflammasomes and autophagy have important roles in the intracellular homeostasis,
inflammation, and pathology; the dysregulation of these processes is often associated with …
inflammation, and pathology; the dysregulation of these processes is often associated with …
EAU guidelines on prostate cancer
G Aus, CC Abbou, M Bolla, A Heidenreich, HP Schmid… - European urology, 2005 - Elsevier
OBJECTIVES:: The first summary of the European Association of Urology (EAU) guidelines
on prostate cancer was published in 2001. These guidelines have been continuously …
on prostate cancer was published in 2001. These guidelines have been continuously …
Drug resistance in metastatic castration-resistant prostate cancer
B Seruga, A Ocana, IF Tannock - Nature reviews Clinical oncology, 2011 - nature.com
Docetaxel in combination with prednisone is the standard of care in men with symptomatic
castration-resistant prostate cancer (CRPC). However, a substantial proportion of men with …
castration-resistant prostate cancer (CRPC). However, a substantial proportion of men with …
Docetaxel: An update on its molecular mechanisms, therapeutic trajectory and nanotechnology in the treatment of breast, lung and prostate cancer
Amongst the various microtubule-targeting agents, Docetaxel (DTX) has gained immense
attention in cancer chemotherapy due to its good therapeutic index. DTX belongs to the …
attention in cancer chemotherapy due to its good therapeutic index. DTX belongs to the …
[PDF][PDF] Guidelines on
A Heidenreich, M Bolla, S Joniau, MD Mason… - Update, 2007 - imop.med.auth.gr
The European Association of Urology (EAU) Guidelines Group for Prostate Cancer have
prepared this guidelines document to assist medical professionals assess the evidence …
prepared this guidelines document to assist medical professionals assess the evidence …
Targeting the NLRP3 inflammasome as a new therapeutic option for overcoming cancer
Simple Summary NLRP3 inflammasome is a cytoplasmic multiprotein complex that
assembles in response to cellular distress and promotes maturation and release of the …
assembles in response to cellular distress and promotes maturation and release of the …
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer
A concurrent multicenter, randomized Phase II trial employing a recombinant poxviral
vaccine provided evidence of enhanced median overall survival (OS)(p= 0.0061) in patients …
vaccine provided evidence of enhanced median overall survival (OS)(p= 0.0061) in patients …